BOSTON, Aug. 1, 2024
/PRNewswire/ -- July 29-31 - The 4th mRNA
Therapeutics Summit, one of the most important conferences in the
global mRNA industry, took place in Boston, USA.
Over 400 industry experts and 65 leading researchers in mRNA
development gathered to discuss the latest breakthroughs and
expanding applications of mRNA technology. Dr Xiangrong Song, co-founder of Chengdu-based WestGene Biopharma, was invited
to attend and share insights into WestGene's pioneering work in
mRNA therapeutics, with a particular focus on the world's leading
EBV-related cancer mRNA therapeutic vaccine, WGc-043.
Highlighting breakthroughs in mRNA therapeutics
Dr. Song presented the latest research data and technological
advancements of WGc-043, the first mRNA therapeutic vaccine
targeting EBV-related tumors to achieve IND milestones in both
China and the US. In her keynote
presentation, Dr. Song detailed the development of WGc-043,
highlighting its safety and efficacy in the treatment of NKT cell
lymphoma (NKTCL) and nasopharyngeal carcinoma (NPC). The vaccine
utilizes WestGene's breakthrough technologies in mRNA sequence
design, novel delivery vectors and scalable manufacturing to ensure
high standards of safety and efficacy.
During the Summit, Dr Song also discussed the broader challenges
and opportunities within the mRNA industry, in particular the need
to improve protein expression and delivery system efficiency while
reducing production costs. She emphasized the importance of
balancing efficacy and safety, a principle that has guided
WestGene's R&D efforts from the outset. Dr. Song also
highlighted WestGene's collaborative approach, which includes
pipeline licensing for access to validated candidates,
co-development projects that leverage combined expertise, and
technology licensing to enable partners to use WestGene's
cutting-edge solutions in their own developments, thus accelerating
innovation and therapeutic advancements.
The Summit featured in-depth discussions on the latest clinical
data, platform development, regulatory insights, and frontier
applications of mRNA therapeutics to address various indications,
including oncological, rare, and infectious diseases.
Dr. Song concluded, "Presenting our research at such platform is
very meaningful. mRNA technology offers new hope and options for
the treatment of malignancies, and our studies underscore the
immense potential of this therapy in terms of safety and
efficacy.
WestGene Biopharma remains committed to pushing the boundaries
of mRNA therapeutics, leveraging its proprietary technologies and
collaborative framework to bring transformative therapies to
patients worldwide.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/westgene-leads-the-way-in-mrna-innovation-at-the-4th-mrna-therapeutics-summit-302213148.html
SOURCE WestGene